- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Emerging agents and regimens for AML ; volume:14 ; number:1 ; day:23 ; month:3 ; year:2021 ; pages:1-20 ; date:12.2021
Journal of hematology & oncology ; 14, Heft 1 (23.3.2021), 1-20, 12.2021
- Creator
-
Liu, Hongtao
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-021-01062-w
- URN
-
urn:nbn:de:101:1-2021050807302756729820
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Liu, Hongtao
- SpringerLink (Online service)
Other Objects (12)
Emerging agents and regimens for multiple myeloma
Emerging agents and regimens for polycythemia vera and essential thrombocythemia
New agents and regimens for diffuse large B cell lymphoma
Clinical results of hypomethylating agents in AML treatment
Emerging therapeutic agents for genitourinary cancers
Emerging therapeutic agents for lung cancer
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
"AML!
AML
AML
Emerging agents and regimens for multiple myeloma
Emerging agents and regimens for polycythemia vera and essential thrombocythemia
New agents and regimens for diffuse large B cell lymphoma
Clinical results of hypomethylating agents in AML treatment
Emerging therapeutic agents for genitourinary cancers
Emerging therapeutic agents for lung cancer
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
"AML!
AML
AML
Emerging agents and regimens for multiple myeloma
Emerging agents and regimens for polycythemia vera and essential thrombocythemia
New agents and regimens for diffuse large B cell lymphoma
Clinical results of hypomethylating agents in AML treatment
Emerging therapeutic agents for genitourinary cancers
Emerging therapeutic agents for lung cancer
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
"AML!
AML